Search Result

Basic Information

Classification Information

Regulatory Mechanism		Biological Function		Clinical Application
TF		Immune		Survival
Enhancer		Apoptosis	apoptosis	Drug
Variant		Cell Growth		Circulating
MiRNA		EMT		Metastasis
Methylation		Coding Ability		Recurrence

Cancer&Entry Information

Cancer Name	multiple myeloma
ICD-0-3	C42.1
Methods	qPCR, Western blot, Luciferase reporter assay, in vitro knockdown
Sample	multiple myeloma plasma, cell lines (NCI-H929, ARH77 and PRMI8226)
Expression Pattern	down-regulated
Function Description	PRAL was downregulated in primary MM cells and cell lines, especially in MM cells with del(17p), and was associated with ISS stage and Durie-Salmon stage in MM patients. Survival curves showed that MM patients with low PRAL expression had a significantly shorter disease-free survival (DFS) and overall survival (OS) than the patients with high PRAL expression. Multivariate Cox regression analysis showed that PRAL expression was an independent predictor for DFS and OS. Then cell proliferation, viability, Ki67 expression, and caspase-3 activity detection showed that PRAL promoted MM cell growth inhibition and apoptosis, and potentiated the anti-MM effect of BTZ in vitro. We further identified and confirmed that miR-210 was the target of PRAL, and miR-210 overexpression overturned the potentiation effect of PRAL on BTZ efficacy. Subsequently, bone morphogenetic protein 2 (BMP2) was confirmed to be the target of miR-210, and PRAL positively regulated the derepression of BMP2 by sponging miR-210. Overexpression of BMP2 potentiated the anti-MM effect of BTZ in vitro.
Pubmed ID	29944867
Year	2018
Title	LncRNA PRAL Is Closely Related to Clinical Prognosis of Multiple Myeloma and the Bortezomib Sensitivity

External Links